NAV

Etidocaine

Identification

Generic Name
Etidocaine
DrugBank Accession Number
DB08987
Background

Etidocaine is marketed under the name Duranest. It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.

Type
Small Molecule
Groups
Approved
Structure
3D
Similar Structures
Weight
Average: 276.417
Monoisotopic: 276.220163528
Chemical Formula
C17H28N2O
Synonyms
  • Etidocaina
  • Etidocaine
  • Etidocainum
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe risk or severity of methemoglobinemia can be increased when Abemaciclib is combined with Etidocaine.
AbirateroneThe risk or severity of methemoglobinemia can be increased when Abiraterone is combined with Etidocaine.
AcetaminophenThe risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Etidocaine.
AcetazolamideThe risk or severity of methemoglobinemia can be increased when Acetazolamide is combined with Etidocaine.
Acetic acidThe risk or severity of methemoglobinemia can be increased when Acetic acid is combined with Etidocaine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Etidocaine hydrochlorideG6N3B3U8E636637-19-1LMWQQUMMGGIGJQ-UHFFFAOYSA-N
International/Other Brands
Duranest (AstraZeneca)

Categories

ATC Codes
N01BB07 — EtidocaineN01BB57 — Etidocaine, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid amides
Alternative Parents
Anilides / m-Xylenes / N-arylamides / Fatty amides / Trialkylamines / Secondary carboxylic acid amides / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alpha-amino acid amide / Amine / Anilide / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxamide group / Fatty acyl / Fatty amide / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
amino acid amide (CHEBI:4904)
Affected organisms
Not Available

Chemical Identifiers

UNII
I6CQM0F31V
CAS number
36637-18-0
InChI Key
VTUSIVBDOCDNHS-UHFFFAOYSA-N
InChI
InChI=1S/C17H28N2O/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5/h9-11,15H,6-8,12H2,1-5H3,(H,18,20)
IUPAC Name
N-(2,6-dimethylphenyl)-2-[ethyl(propyl)amino]butanamide
SMILES
CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C

References

Synthesis Reference

U.S. Patent 3,812,147.

General References
Not Available
KEGG Drug
D04095
KEGG Compound
C07530
PubChem Compound
37497
PubChem Substance
310264948
ChemSpider
34400
BindingDB
50225497
RxNav
4171
ChEBI
4904
ChEMBL
CHEMBL492
Wikipedia
Etidocaine

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)203-203.5U.S. Patent 3,812,147.
Predicted Properties
PropertyValueSource
Water Solubility0.19 mg/mLALOGPS
logP3.05ALOGPS
logP4.46Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)13.62Chemaxon
pKa (Strongest Basic)8.59Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area32.34 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity87.47 m3·mol-1Chemaxon
Polarizability33.47 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fb9-1920000000-366c91e9bec7c661b68d
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-00b9-1790000000-7517a4c3fe10a56458b5
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-4900000000-5698178a8e4c55dc004d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00di-2920000000-9a94b5472cdadb7a9d68
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0h2f-5900000000-03cae2eb70a922311c26
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-006x-7920000000-09ef16d859b9b11ebad2
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-169.0937
predicted
DeepCCS 1.0 (2019)
[M+H]+171.4517
predicted
DeepCCS 1.0 (2019)
[M+Na]+177.54485
predicted
DeepCCS 1.0 (2019)

Drug created at June 10, 2014 21:18 / Updated at February 02, 2024 22:54